---
created: 2025-04-13
updated: 2025-04-13T10:53
id: iL$Dy=2[%=
specialty: patho
specialty_id: 149
tags:
  - source/ak-original-decks::step-1::zanki-step-decks::zanki-immunology-+-general-pathology::pathoma-chapter-3-(neoplasia)
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::08-oncogenes
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::08-oncogenes::signal-transducers::bcr-abl
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::04-pathology::28-leukemia::acute-leukemia::acute-lymphoblastic-leukemia::b-all
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::04-pathology::29-chronic-myeloproliferative-disorders
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::04-pathology::29-chronic-myeloproliferative-disorders::chronic-myelogenous-leukemia
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::13-hematology-oncology::18-myeloproliferative-disorders
  - "source/ak-step1-v11:": 
  - theme/pathoma::03-neoplasia::02-carcinogenesis::2-oncogenes
  - "source/ak-step1-v11:": 
  - theme/pathoma::03-neoplasia::02-carcinogenesis::2-oncogenes::table-3.3-important-oncogenes::signal-transducers
  - "source/ak-step1-v11:": 
  - theme/pathoma::03-neoplasia-alt-tagging::bluegalaxies::02-carcinogenesis::2-oncogenes
  - "source/ak-step1-v11:": 
  - theme/pathoma::03-neoplasia-alt-tagging::bluegalaxies::02-carcinogenesis::2-oncogenes::signal-transducers
  - "source/ak-step1-v11:": 
  - theme/physeo::11-pathology::07-general-pathology::09-carcinogenesis
  - "source/ak-step1-v11:": 
  - theme/physeo::11-pathology::10-hemeonc-pathology::14-myeloproliferative-disorders
  - "source/ak-step1-v11:": 
  - theme/pixorize::01-immunology::07-leukemias-&-lymphomas::03-cml
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::22-onc-drugs::18-imatinib,-dasatinib
  - "source/ak-step1-v11:": 
  - theme/sketchypath::10-myeloid-&-lymphoid::01-myeloid-disorders::01-myeloproliferative-neoplasms-&-myelodysplastic-syndromes
  - "source/ak-step1-v11:": 
  - theme/sketchypath::10-myeloid-&-lymphoid::01-myeloid-disorders::02-acute-myeloid-leukemia-(aml)-&-chronic-myeloid-leukemia-(cml)
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::12000-12999::12278
  - source/ak-step1-v11::^other::^expn::bgadd
  - source/ak-step1-v11::^other::^fa-updates::fa2018"
type: flashcard
---

# Question
Translocations of the ABL proto-oncogene with the Breakpoint Cluster Region (BCR) = BCR-ABL1 fusion gene = on chromosome **22** are associated with:   - **CML**  - **adult ALL**    * Bonus: What are the main tumor promoter aka protooncogenes?

---

# Answer
- RT-PCR = diagnose CML by identifying = mRNA transcript containing both BCR and ABL exons in affected cells.    - Reverse transcription polymerase chain reaction (RT-PCR) is used to detect and quantify levels of mRNA in a sample   - It creates a complementary DNA template that is then amplified using the standard PCR procedure   BCR-ABL = the resulting fusion gene of t(9;22) encodes a protein with inc tyrosine kinase activity that inhibits apoptosis while promoting mitogenesis  The pathophysiology of chronic myelogenous leukemia (CML)   In CML, translocation between c(9; 22).   - The ABL proto-oncogene is transported from c9 to c22 where it is placed adjacent to the BCR gene.   - The resulting oncogene, BCR-ABL, codes for a fusion protein with constitutively active tyrosine kinase activity.   - This protein stimulates the proliferation of granulocytic precursors == development of CML.   - The kinase activity of this fusion protein is a target of the protein kinase inhibitor, imatinib.